Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report

Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report

Abstract Durvalumab is a humanized monoclonal antibody targeting programmed cell death ligand‐1 (PD‐L1), leading to an antitumor activity, used as consolidation therapy in patients with locally advanced unresectable non‐small cell lung cancer (NSCLC). Several immune‐related adverse events (irAEs) ha...

Full description

Bibliographic Details
Main Authors: Maël Domblides, Margaux Geier, Chantal Decroisette, Renaud Descourt
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Thoracic Cancer
Subjects:
immune‐related adverse event
lung cancer
bronchiectasis
durvalumab
panbronchiolitis
Online Access:https://doi.org/10.1111/1759-7714.13862

Internet

https://doi.org/10.1111/1759-7714.13862

Similar Items